Belimumab treatment for adults with systemic lupus erythematosus a review of clinical effectiveness, cost-effectiveness, and guidelines

Systemic lupus erythematosus (SLE) is a chronic, remitting autoimmune disease related to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee did not recommend listing belimumab in public drug formularies in 2012. The recommendation was based...

Full description

Main Authors: Chao, Yi-Sheng, Adcock, Lorna (Author)
Corporate Authors: Canadian Agency for Drugs and Technologies in Health, Canadian Agency for Drugs and Technologies in Health Rapid Response Service
Format: eBook
Language:English
Published: Ottawa CADTH 2018, May 23, 2018
Edition:Version: 1.0
Series:CADTH rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Systemic lupus erythematosus (SLE) is a chronic, remitting autoimmune disease related to autoantibody production and abnormal B lymphocyte function. In Canada, the Common Drug Review (CDR) committee did not recommend listing belimumab in public drug formularies in 2012. The recommendation was based on two major randomized controlled trials. Recently, new trials examining belimumab have been published and it is unclear whether the latest evidence would support or change the 2012 Centre for Reviews and Dissemination (CDR) recommendation. The objective of this report is to review the latest evidence in order to further determine the clinical and cost-effectiveness of belimumab for the treatment of systemic lupus erythematosus (SLE), as well as to review the evidence-based guidelines
Physical Description:1 PDF file (30 pages)